A wave of fresh discoveries is reshaping biotech research. Scientists have, for the first time in yeast, combined optogenetics with three‑level CRISPR control—tuning gene transcription, protein production, and function with light to build faster, more reliable synthetic circuits. In a parallel study, researchers uncovered why a tick‑borne virus (WELV) devastates the liver: it triggers both cell‑death fireworks (pyroptosis) and a lipid‑fuel overhaul, driven by the protein GSDME, opening doors for repurposed drugs. Bone health got a boost from a newly engineered sulfated chitosan that locks onto a specific spot on the RANK receptor, halting bone‑eating cells while preserving their growth‑supporting signals. In Parkinson’s research, a team revealed how the enzyme CH25H blocks the clearance of toxic α‑synuclein, and how short peptides can release this brake, suggesting fresh therapeutic angles. Meanwhile, Wuhan University showed how bacteriophages masquerade as “self” by hijacking a host sulfur‑transfer enzyme, evading bacterial immune defenses. Other highlights include a nanopore‑based method that reads single‑molecule peptide sequences, an atomic‑scale map of collagen fiber ordering, and insights into how viruses hijack autophagy pathways for replication. Finally, a novel CAR‑T design using parallel 4‑1BB signals promises longer‑lasting, more potent T cells against small‑cell lung cancer, while a new macrophage‑driven pathway explains chemotherapy‑induced heart damage, suggesting targeted interventions.
Read more